Radical Experiment Changing the Way Big Pharma Innovates
The Fortune website noted that in the highly competitive, IP-obsessed world of drug development, throwing open the doors and inviting people in, is a departure in strategy to say the least. Yet, such is the surprising concept behind JLABS, the “no strings attached” incubator that Johnson & Johnson launched near San Diego in 2012, and has since rolled out to five other sites in North America. The incubators are also just one of piece of the radical “open innovation strategy” J&J’s Chief Scientific Officer Paul Stoffels has crafted for the company. For Stoffels opening the company’s R&D space to outsiders made good strategic sense: It was a way to accelerate innovation in the scientific community and to develop relationships with innovators.
Click here to read the full article.